Stay updated on Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.

Latest updates to the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page
- ChecktodayChange DetectedThe page’s revision tag was updated from v3.5.2 to v3.5.3, indicating an incremental update to the site software. This change is a metadata-level modification and does not affect the study details or visible content.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a minor patch with no changes to core page content.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded Extranodal nasal NK/T cell lymphoma and CD4+/CD56+ hematodermic neoplasm to the study's listed conditions.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.2 was added and the previous funding/operation-status notice (Revision: v3.4.1) was removed; these are minor site maintenance updates that do not affect study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.